Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Dig Dis Sci ; 52(8): 1995-2005, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17406843

RESUMO

In this study, we assessed the hypothesis that the expression of angiotensin II receptor type 1 (AGTR1) in liver tissue changes with increasing fibrosis, which would influence the antifibrotic efficacy of AGTR1 blockers. Rats were treated with candesartancilexetil (CAN) initiated 8 or 15 days after bile duct occlusion (BDO). Four weeks after BDO, AGTR1 mRNA and protein were decreased compared to those in sham-operated animals depending on the amount of fibrosis. Starting CAN early, but not late, reduced mRNA of profibrotic TGF-beta, MMP2, and Smad2. However, CAN had no significant effect on collagen I, fibrosis, or intrahepatic resistance. In conclusion, progression of liver fibrosis reduces AGTR1 expression. Therefore, in our model, antifibrotic effects of CAN are insufficient to improve fibrosis or intrahepatic resistance. However, if AGTR1 blockade is started early, a decrease in essential profibrotic molecules is achieved. Hence, early initiation of therapy with AGTR1 blockers may be crucial for the prevention of cirrhosis.


Assuntos
Cirrose Hepática/metabolismo , Receptor Tipo 1 de Angiotensina/análise , Animais , Benzimidazóis , Compostos de Bifenilo , Colágeno Tipo I/análise , Progressão da Doença , Fígado/química , Cirrose Hepática/induzido quimicamente , Cirrose Hepática/prevenção & controle , Masculino , Metaloproteinase 2 da Matriz/análise , Ratos , Ratos Wistar , Proteína Smad2/análise , Tetrazóis , Fator de Crescimento Transformador beta/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...